Drug Profile
BMS 936559
Alternative Names: Anti PD L1; BMS-936559; MDX-1105; PD-L1 inhibitor - Bristol-Myers SquibbLatest Information Update: 08 Dec 2021
Price :
$50
*
At a glance
- Originator Medarex
- Class Antineoplastics; Antiretrovirals; Antiseptics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; HIV infections; Sepsis; Solid tumours
Most Recent Events
- 14 Sep 2017 Bristol-Myers Squibb terminates due to change in business objectives its phase I/II trial in Sepsis in USA (IV, Infusion) (NCT02576457)
- 22 Feb 2016 Pharmacokinetics and adverse event results from a phase I trial in HIV Infections presented at 23rd Conference on Retroviruses and Opportunistic Infections (CROI-2016)
- 01 Dec 2015 Phase-I/II clinical trials in Sepsis in USA (IV, Infusion) (NCT02576457)